THE ROLE OF AFLIBERCEPT IN THE TREATMENT OF METASTATIC COLORECTAL CANCER


A.A. Mescheryakov

FSBI "Russian Oncological Research Center n.a. N.N. Blokhin" RAMS, Moscow
Aflibercept is one of the latest targeted drugs with proven efficacy in the treatment of patients with metastatic colorectal cancer. The drug is approved for the second line treatment in combination with FOLFIRI scheme after applying the oxaliplatin-containing chemotherapy regimens. The review presents the general data on the tumor angiogenesis, the mechanism of action of aflibercept, and the results of the application of anti-angiogenic therapy in the first and second lines of the drug treatment of metastatic colorectal cancer.

About the Autors


A.A. Mescheryakov – PhD in Medical Sciences, Senior Scientist, FSBI "Russian Oncological Research Center n.a. N.N. Blokhin" RAMS, Moscow; e-mail: a_meshcheryakov@mail.ru


Similar Articles


Бионика Медиа